IN 1912, Boveri (1) proposed that chromosome changes are important in the etiology of tumors. As improved cytologic techniques were later developed, it became apparent that tumor cells have mitotic abnormalities such as nondisjunction and lagging chromosomes. For most tumors karyotypic changes vary among different individuals. Within a single individual, however, the chromosome pattern remains constant, though clonal evolution of abnormal karyotypes may occur. This constant pattern in an individual has led to a theory of tumor progression that the basic line or stemline in a tumor is clonal in origin and may contain a particular constant chromosome abnormality (2) . Cells with this abnormality appear to have a selective advantage and proliferate, often at the expense of the normal cells. The use of genetic markers supports this theory of clonal origin for some tumors (3) . In most instances, the chromosome changes denote somatic mutations in the affected tissues, since a normal karyotype is observed in unaffected cells.
The karyotypic variability suggested that the chromosome changes were merely an epiphenomenon and were not involved in the initiation of disease (4) . Consistent abnormalities were found in two conditions, however. The Philadelphia (Ph l ) chromosome (previously thought to be a partial deletion of the long arm of one G chromosome) is found in the marrow cells of most patients with chronic myelogenous leukemia (CML) (5) . One G chromosome is missing in tumor cells of most meningiomas (6) (7) (8) .
New staining techniques with quinacrine fluorescence (9) , Giemsa banding (10), or both, are useful for re-examining the karyotypes of affected cells. It is now possible to determine whether there is a nonrandom association between specific chromosome abnormalities and particular tumors or potentially malignant disorders. Furthermore, chromosome abnormalities regularly associated with a disorder can be distinguished from those that are sporadic.
I present a hypothesis proposing a specific relationship between chromosomes and etiologic agents of various tumors. The scope of the terms "tumor" and "etiologic agent" should be clarified. Whereas most specific pathologic processes discussed in this paper are tumors, the neoplastic nature of some is debatable; therefore, the term "disease" is used in some instances. For the same reason, the term "oncogenic" agent is too restrictive; the terms "mutagenic" or "etiologic" agent are more suitable.
The following postulates are based largely on data obtained from animal experiments. As will become evident later, it is impossible to perform many of these studies in man. However, data now available suggest \ that chromosome abnormalities in many diseases of I man are not random. POSTULATES I) Susceptibility of an individual to a mutagenic agent is a function of his genetic constitution.
2) For individuals of a given species, each class of mutagenic agents produces a different pattern of chromosome abnormalities within cells from susceptible tissues.
3) The diseases produced in individuals of the same species by different classes of agents may appear clinically and histologically indistinguishable.
HYPOTHESIS
a) The chromosome pattern within affected cells may be consistent for a disease produced by a single etiologic agent (or possibly several closely related agents).
b) The chromosome pattern may be highly variable for a given disease that can be produced by different etiologic agents.
c) Within a disease category, it may be possible to distinguish individuals whose affected cells have the same chromosome abnormality and thus to identify those whose disease may be due to the same etiologic agent.
d) The converse of c)-that a single etiologic agent may cause the same chromosome abnormality in cells from each individual-is probably less valid for a genetically heterogeneous population.
Evidence suggesting a specific chromosome abnormality-"tumor" relationship for certain conditions in man is summarized in table I. The affected cells have a relatively consistent chromosome pattern in CML, meningioma, and Burkitt's lymphoma. The chromosomes analyzed by standard techniques show a variable pattern in the affected cells of the other 3 conditions. Some of these observations have limited value because the techniques could not precisely identify the specific chromosomes involved and the sites of chromosome breakage and rearrangement. However, certain consistent "chromosome subgroups" may be detectable when cells from patients with the latter diseases are analyzed with more sophisticated cytogenetic techniques.
DISEASES WITH A CONSISTENT CHROMOSOME PATTERN

CML
The chromosome changes of peripheral blood and bone marrow leukocytes in patients with CML have been studied extensively with standard cytogenetic techniques, and a consistent pattern has emerged. Approximately 90% of these patients have the Phl chromosome (I1, 12); most of the remaining 10% have an apparently normal karyotype. These Phl-negative patients are clinically different: They are older, have lower leukocyte and platelet counts, and usually do not respond as well to busulfan treatment as do the Phl-positive patients (I1, 12) . Their life expectancy is shorter-IS months as compared with 40 months for Phl-positive patients (11) .
Phl is a chromosome #22 that is lacking most of its long arm (22q-) (I3, 14) ; Rowley ( , and in 5 patients it was thought to be an isochromosome for the long arm of #17 (17) . In 4 of 5 patients with the double Phi, the 2 Phl chromosomes appeared identical (15, 16 ).
Meningioma
The characteristic cytogenetic feature of cells from human meningiomas is the loss of 1 G chromosome (6) (7) (8) , recently identified as #22 (18, 19) . In a few tumors (5/70), part of the long arm of I G chromosome appears deleted; it is also a #22 (20) . Since the chromosome abnormality in both CML and meningioma involves chromosome #22, a similar etiologic agent may cause both conditions. This suggestion might be incorrect, however, because published karyotypes from several meningiomas appear to have a normal #9 (19) . The C chromosome that may be missing in cells from several of these tumors has been identified as #8 (I9).
Burkitt's Lymphoma
A secondary constriction near the end of the long arm of I C chromosome has been observed in a variable proportion of cells from some cultured Burkitt's lymphoma cell lines (21, 22) . A similar secondary constriction was present in =9% (2-25%) of normal human cells cultivated with a) lethally irradiated cells from Burkitt's lymphoma cell lines (23), or b) a filtrate of cells containing a herpes-like virus (24) . The identity of the C chromosome carrying the secondary constriction has not been reported, but analysis of I photograph in which the chromosomes have faint bands [ fig. 3 in (21)] suggests that it may be #11. The constriction was not seen in direct chromosome preparations of 4 Burkitt's tumors (21) .
A consistent chromosome abnormality was observed only when cells from Burkitt's tumors and. cell lir:es established from these tumors were exammed with quinacrine fluorescence. An extra band of medium fluorescence was noted at the end of I chromosome #14 in every cell of 5 of 6 tumor biopsy specimens and 7 of 9 tumor cell lines (25) . Whether the extra band was a duplication of a segment of #14 or the n;sult of a translocation was not determined.
DISEASES WITH AN APPARENTLY VARIABLE CHROMO-SOME PATTERN Acute Myelogenous Leukemia (AML)
Chromosome abnormalities detectable by standard techniques have been identified in bone marrow cells from 30-100% (26-28) of patients with AML. In most cases, the modal chromosome number ranged from 40 to 60 or 90 to 100, and the abnormal pattern was highly variable. Groups C, D, E, and G had gains and losses of chromosomes more frequently than expected (28). t In 1 patient the entire short arm and one-third the long arm of #22 were deleted.
The new techniques have been used to identify patients whose cells show similar chromosome abnormalities. Marrow cells with a hypodiploid chromosome number were found in 3 female patients with AML. Cells from 2 of these had an identical complex karyotype (29) , which suggests that chromosome abnormalities in this disease may not be entirely random. Cells from both patients had 45 chromosomes and were lacking an X. In addition, a portion of the long arm of 1 #8 was translocated to I #21; this produced 2 translocation chromosomes, I of which resembled a # 16 and the other, a D chromosome. The breaks in 8q and 21q appeared to occur in the same bands in both patients. The translocation was assumed to be reciprocal. The karyotype can be expressed as 45,X, t(8;21)(q22;q22) (30) . The marrow of both patients showed a predominance of myeloblasts, and both had a rapidly fatal course.
Polycythemia Vera (PV)
Variable chromosome abnormalities were observed in bone marrow cells from approximately 22% of patients with PV (31), whether or not they were treated. The arm of I F chromosome (F? --) was deleted in cells from = 15% (31) of patients with PV (more than half of all patients with abnormalities). Three patients whose cells contained normal F chromosomes on initial examination showed the F?-chromosome after treatment with 32P, X-rays, or busulfan. This suggests that the F chromosome of patients with PV has a site particularly susceptible to the action of mutagenic agents. Alternatively, the F? -clone of cells may have been present before treatment, but in such small numbers that the clone was not detected until later in the disease. Abnormalities of F chromosomes also have been reported in some patients with idiopathic sideroblastic anemia (ISA) (32) . Both diseases have increased risk of termination in acute leukemia.
In Giemsa banding (33) and quinacrine fluorescence (16) studies, the F?-in PV has been identified as a #20 chromosome that has lost approximately half to two-thirds of its long arm (20q -); whether the material missing from the #20 has been translocated to another chromosome is uncertain. Sometimes the short arm of the same #20 appears slightly smaller than its homologue (16). Patients whose cells show the 20q -chromosome in the polycythemic phase keep this abnormality, and the cells show additional abnormalities in the acute leukemic phase (16, 31). Cells from 1 'patient with leukemia had 2 20q-chromosomes (16), a phenomenon analogous to the double Ph! in the acute phase of CML.
Myelodysplasia
The significance of the chromosome abnormalities in marrow cells of some patients with other hematologic disorders is uncertain. Aneuploidy is an early change in some patients who later develop leukemia (34); in others, the karyotypic change is stable and may persist for several years. I studied 1 such patient with thrombocytosis, who had 2 extra C chromosomes in some marrow cells for 8 years without any disease progression (35) . It is possible that all patients with aneuploid cells in the marrow will develop leukemia if they live long enough, and that our period of observation is too short compared with the time of evolution of the disease. Alternatively, various chromosomes may be involved because of the action of different etiologic agents, and these chromosomes may differ in their prognostic significance.
The abnormality most frequent in marrow cells of patients with aneuploidy is 1 or 2 additional C chromosomes, regardless of whether the diagnosis is leukemia, PV, or a "nonmalignant" hematologic disorder. Preliminary evidence from 5 patients with CML in the acute phase (15, 16) and from 2 with marrow aplasia and granulocytopenia (36) suggests that chromosome #8 may be involved more frequently than expected by chance. In 3 of 5 meningiomas, 1 #8 chromosome was missing (19) . Trisomy #8 is the only constitutional chromosome abnormality (i.e., all cells are abnormal) that involves a C group trisomy identified thus far (37) . This may indicate that abnormalities of the genetic material carried on #8 are less deleterious to the individual, and that excesses or deficiencies can be tolerated as somatic mutations more readily than other types of chromosome imbalance. On the other hand, some genetic information carried on #8 may be important in the development of diseases in which #8 is abnormal because of excess, deficiency, or translocation of its chromosome material.
Consistent chromosome rearrangements have been observed in 3 diseases discussed here. A specific translocation involving #9 and 22 is thought to be associated with CML (J 5). Whether a specific translocation also occurred in cells with the 20q -chromosome (PV) or the 14q+ chromosome (Burkitt's lymphoma) has not been determined. It is presently impossible to decide whether some agen t causes a particular chromosome change simultaneously with the tumor or premalignant state, or whether chromosome changes occur spontaneously and only the chance occurrence of a specific chromosome change leads to tumor formation. Careful cytogenetic analysis of cells from many neoplastic and preneoplastic conditions should help distinguish these possibilities as well as others.
SPECIFIC CHROMOSOME ABNORMALITIES INDUCED IN ANIMALS AND IN VITRO
Nonrandom chromosome abnormalities occur in some animals exposed to chemical and viral mutagenic agents; e.g., trisomy for the largest telocentric chromosome in rats was observed in leukemia (38) (39) (40) and sarcomas (41) (38, 40) . A different, but very consistent karyotypic pattern was seen in sarcomas induced in the rat by Rous sarcoma virus (RSV) (42) . The pattern of karyotypic evolution involved additions of I medium-size telocentric chromosome, followed by I medium and I small subtelocentric chromosome. Chromosomes most frequently abnormal in DMBA-induced tumors were rarely abnormal in RSV-induced tumors, and vice versa. The sarcomas produced by DM BA and RSV were histologically indistinguishable.
A similar phenomenon was observed in the Chinese hamster. One or more additional chromosomes belonging to 3 pairs (#5, 6, or 10) were found in most sarcomas induced by RSV (43), whereas #11 was the most frequent addition in cells from DMBA-induced sarcomas (44) in the same inbred Chinese hamster strain.
Even in experimental animals, some chromosome variability was present in tumors induced with a single, known oncogenic agent. It may be significant, however, that chromosome variability was less in inbred (20-30%) than in randombred (about 50%) animals.
Various in vitro systems also have been used to study the association of chromosome abnormalities with malignancy. Harris, Klein, and co investigators (45, 46) found that hybrid cells, formed by fusion of malignant and nonmalignant cells, produced an increasing number of tumors in vivo as they lost certain specific, but as yet unidentified, chromosomes. The authors concluded that malignancy behaves like a recessive trait. Quinacrine fluorescence has been used to compare the karyotype of a nonmalignant L cell line and its malignant derivative (47) . The significance of the chromosome differences between the 2 cell lines is not known but can be determined by analysis of additional cell lines.
Other investigators proposed that malignant cell transformation and its reversion are controlled by the balance between genes for expression and genes for suppression of malignancy (48) . The chromosomes of golden hamster cells transformed with a chemical carcinogen (dimethylnitrosamine) have been analyzed with one of the new Giemsa banding techniques (10) . The transformed cells had a consistent chromosome pattern different from that observed in less malignant revertant cells (49) . These cells produced tumors when they were injected into animals; the cells from these tumors also showed a consistent karyotype. The close association of gains or losses of particular chromosomes with the malignant or nonmalignant character of tb/"· cells supports the above proposal.
MECHANISMS PRODUCING CHROMOSOME ABNORMAL-ITIES SPECIFIC FOR DIFFERENT ETIOLOGIC AGENTS
One mechanism that could account for the chromosome differences observed with different oncogenic agents is suggested by an observation of Sugiyama (50), who noted that 2 regions on the long telocentric chromosomes, frequently present in a trisomic state in DMBA-induced rat leukemia, were specifically vulnerable to the chromosome-damaging action of DMBA. These same regions were late replicating and heterochromatic. It has been known for some time that such regions show preferential susceptibility to mutagenic agents (51) .
A nonrandom effect on human chromosomes-the production of gaps and breaks at a specific site on chromosome #17-was observed in cells infected with adenovirus types 12 and 31, and to a lesser extent with type 18; infection with types 2 and 7 resulted in randomly distributed aberrations (52) . A secondary constriction, indicating a heterochromatic region, was observed in the same specific site on #17 (53) . In some circumstances, types 12, 18, and 31 are highly oncogenic in hamsters, type 7 is moderately oncogenic, and type 2 is nononcogenic (54) . A similar nonrandom secondary constriction has been discussed in connection with Burkitt's lymphoma (21) (22) (23) (24) .
Various hypotheses concerning the role of genetic change and carcinogenesis are under investigation. In many autosomally recessive diseases in humans [including Fanconi's anemia (55), Bloom's syndrome (56) , and ataxia telangiectasia (57) ], a tendency to chromosome breakage and rearrangement is observed in in vitro cultures. Cells from patients with Fanconi's anemia (58), but not with Bloom's syndrome, have an increased susceptibility to viral transformation (59) . Patients with these disorders have a greater than normal frequency of leukemia and other malignancies (55) (56) (57) . The chromosome pattern in many of these individuals may be variable or normal. Hecht et al. (60) recently summarized data on the chromosome pattern of lymphocytic clones in 6 patients with ataxia-telangiectasia. All 6 had rearrangements involving a D chromosome, and 2 studied with the new techniques had a break in the long arm of#14.
The observation that at least part of the genome of oncornaviruses may be integrated in apparently normal host cells has led Huebner and Todaro (61) to propose the "oncogene" hypothesis-that the "oncogene," part of the oncornavirus genome existing as the DNA provirus, is included in the normal gene pool of all vertebrates and is transmitted vertically by the usual mechanisms of inheritance.
The relationship of the "oncogene" hypothesis to that proposed here is not clear. Possibly different "oncogenes" have different chromosome locations. Recent work, in which various genetic loci associated with susceptibility to murine leukemia virus (MuLV) are mapped to separate but specific chromosomes in inbred mice (62) (63) (64) , supports this suggestion. The relationship of these gene loci to potential specific chromosome abnormalities in the mouse has not been determined. The establishment of linkage for a locus in a particular strain of mice carries no assurance that the same gene or its alleles will occupy the same site in the genomes of other mice (64) . The mapping of genes was possible only with inbred mice and selected backcrosses of known genotype. This method is clearly not applicable to man.
CONCLUSIONS
The experimental data from animals are summarized as follows: 1) Genetic factors, which segregate in a Mendelian fashion and can be located on a specific mouse chromosome, control the susceptibility or resistance of a particular inbred mouse strain to infection with MuLV. 2) In a susceptible strain of rat or Chinese hamster, the particular chromosome abnormality observed depends on the mutagenic agent used in the experiment. 3) Histologically similar tumors caused by different agents have different karyotypic patterns.
The data collected about man are summarized as follows: 1) The relative importance of genetic and environmental factors in tumor production has not been determined. However, families as well as ethnic groups differ in the type and frequency of various tumors. 2) Cells from some types of tumors have a consistent chromosome pattern; Epstein-Barr virus is closely associated with, and has been proposed as, the etiologic agent for Burkitt's lymphoma (65) , which is one of these tumors. 3) Cells from other diseases, including tumors, have a variable chromosome pattern; no specific etiologic agent has yet been identified for any of these diseases.
If the hypothesis proposed here is correct, one would expect to find that CML with the PhI chromosome, meningiomas lacking chromosome #22, and Burkitt's lymphomas with the l4q + chromosome have a specific etiologic agent different from the agent producing the chromosomally normal variant of each disease.
Furthermore, in the acute leukemias, PV, and other myeloproliferative disorders, one would expect to find a diversity of etiologic agents associated with their variable chromosome pattern. Within a disease category, however, careful karyotypic analysis should reveal patients with a similar karyotypic pattern whose disease is due to a single etiologic agent.
